Insider Buying Continues in a Down‑Trended Stock
On May 1 2026, President Heshmatpour Amir F executed a purchase of 10 000 shares of NeOnc Technologies Holdings at $4.16 per share, bringing his total ownership to 3.072 million shares. The transaction occurred immediately after the company’s share price dipped to $4.11. Social‑media sentiment remained essentially neutral, with no discernible shift in market mood or buzz.
Despite a 31 % decline this year, the steady stream of insider purchases provides a notable contrarian signal.
What Does This Mean for Investors?
Insider buying in a declining security often indicates that management believes the shares are undervalued or that upcoming catalysts may reverse the trend. Heshmatpour’s cumulative purchases—10 000 shares per week since late April—illustrate a disciplined, long‑term commitment.
For equity holders, the consistent buys could temper the perception that NeOnc’s stock is purely speculative. However, the company’s 52‑week low of $3.20 and a market cap barely above $100 million keep the risk profile high. Investors should weigh the insider confidence against the company’s clinical pipeline status, which remains in early‑stage trials and faces significant regulatory hurdles.
A Profile of the President’s Trading Habits
Heshmatpour Amir F’s transaction history shows a preference for incremental, low‑cost purchases rather than large, market‑moving trades.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026‑05‑01 | Heshmatpour Amir F (President) | Buy | 10 000 | 4.16 | Common Stock |
| — | Heshmatpour Amir F | Holding | 256 120 | — | Common Stock |
| — | Heshmatpour Amir F | Holding | 550 000 | — | Common Stock |
| — | Heshmatpour Amir F | Holding | 3 714 020 | — | Common Stock |
From April 2 to April 28, he bought 10 000–20 000 shares at prices ranging from $4.52 to $6.32, averaging about $5.10 per share. His most expensive single purchase was on April 6 at $6.32.
The pattern of frequent, modest buys indicates a strategy aimed at building stake without creating price volatility. Historically, Heshmatpour has also maintained significant holdings in related entities—such as AFH Holding & Advisory (3.7 million shares) and HCWG LLC—suggesting a broader investment portfolio aligned with NeOnc’s strategic objectives.
Looking Ahead: Pipeline and Market Dynamics
NeOnc’s flagship candidates, NEO100 and NEO212, are still in Phase I/II trials, meaning that meaningful positive data could be years away. Until then, the company’s valuation is largely driven by speculative expectations.
The current insider buying trend may buoy confidence in a short‑term turnaround, but investors should monitor upcoming clinical milestones, regulatory filings, and any changes in the company’s capital structure. If NeOnc delivers encouraging data or secures additional funding, the share price could recover from its current 52‑week low and validate the insider bets. Until that happens, the stock remains a high‑risk play best suited for investors comfortable with volatility and long‑term horizons.
